Summary
The recent therapeutic approach in which drug candidates are designed to possess diverse pharmacological properties and act on multiple targets has stimulated the development of the multimodal drugs, ladostigil (TV3326) [(N-propargyl-(3R) aminoindan-5yl)-ethyl methyl carbamate] and the newly designed multifunctional antioxidant iron chelator, M-30 (5-[N-methyl-N-propargylaminomethyl]-8-hydroxyquinoline). Ladostigil combines, in a single molecule, the neuro-protective/neurorestorative effects of the novel anti-Parkinsonian drug and selective monoamine oxidase (MAO)-B inhibitor, rasagiline (Azilect, Teva Pharmaceutical Co.) with the cholinesterase (ChE) inhibitory activity of rivastigmine. A second derivative of rasagiline, M-30 was developed by amalgamating the propargyl moiety of rasagiline into the skeleton of our novel brain permeable neuroprotective iron chelator, VK-28. Preclinical experiments showed that both compounds have anti-Alzheimer’s disease activities and thus, the clinical development is oriented toward treatment of this type of dementia. This review discusses the multimodal effects of two rasagiline-containing hybrid molecules, namely ladostigil and M-30, concerning their neuroprotective molecular mechanisms in vivo and in vitro, including regulation of amyloid precursor protein processing, activation of protein kinase C, and mitogen-activated protein kinase signaling pathways, inhibition of cell death markers and upregulation of neurotrophic factors. Altogether, these scientific findings make these multifunctional compounds potentially valuable drugs for the treatment of Alzheimer’s disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Youdim MB, Maruyama W, Naoi M. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor anti-Parkinsonian drug, rasagiline. Drugs Today 2005;41:369–391.
Rabey JM, Sagi I, Huberman M, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson’s disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 2000;23:324–330.
Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59: 1937–1943.
Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59: 1937–1943.
Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62:241–248.
Maruyama W, Nitta A, Shamoto-Nagai M, et al. N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem Int 2004;44:393–400.
Maruyama W, Youdim MBH, Naoi M. Antiapoptotic properties of rasagiline, N-propargylamine-l(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann N Y Acad Sci 2001;939:320–329.
Maruyama W, Akao Y, Youdim MBH, Boulton AA, Davis BA, Naoi M. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3 phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem 2001;78:727–735.
Akao Y, Maruyama W, Shimizu S, et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 2002;82:913–923.
Maruyama W, Akao Y, Youdim MBH, Naoi M. Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)-and (S)-aminoindan, rasagiline and TV1022. J Neural Transm 2000;60:171–186.
Maruyama W, Akao Y, Carrillo M, Kitani K, Youdium M, Naoi M. Neuroprotection by propargylamines in Parkinson’s disease. Suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 2002;24:675–682.
Maruyama W, Takahashi T, Youdim MBH, Naoi M. The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 2002;109:467–481.
Finberg JP, Lamensdorf I, Weinstock M, Schwartz M, Youdim MBH. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol 1999;80:495–499.
Heikkila RE, Duvoisin RC, Finberg JP, Youdim MBH. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol 1985;116:313–317.
Speiser Z, Mayk A, Eliash S, Cohen S. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm 1999;106:593–606.
Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol 1999;366:127–135.
Youdim MBH, Amit T, Yogev-Falach M, Bar-Am O, Maruyama W, Naoi M. The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-parkinson drug, rasagiline. Biochem Pharmacol 2003;66:1635–1641.
Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MBH. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. Faseb J 2004;18:1471–1473.
Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, M.B.H Y. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J Neurochem 2004;89:1119–1125.
Bar-Am O, Weinreb O, Amit T, Youdim MB. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. Faseb J 2005;19:1899–1901.
Yogev-Falach M, Amit T, Bar-Am O, Sagi Y, Weinstock M, Youdim MBH. The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. Faseb J 2002;16:1674–1676.
Yogev-Falach M, Amit T, Bar-AM O, Youdim MBH. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. Faseb J 2003;17: 2325–2327.
Akao Y, Maruyama W, Yi H, et al. An anti-Parkinson’s disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SHSY5Y cells. Neurosci Lett 2002;326:105–108.
Weinreb O, Amit T, Bar-Am O, Chillag-Talmor O, Youdim MBH. Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann N Y Acad Sci 2005;1053:348–355.
Ku WC, Cheng AJ, Wang TC. Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture. Biochem Biophys Res Commun 1997;241:730–736.
Gekeler V, Boer R, Uberall F, et al. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance. Br J Cancer 1996;74:897–905.
Rogers JT, Lahiri DK. Metal and inflammatory targets for Alzheimer’s disease. Curr Drug Targets 2004;5:535–551.
Joseph JA, Shukitt-Hale B, Casadesus G, Fisher D. Oxidative stress and inflammation in brain aging: nutritional considerations. Neurochem Res 2005;30:927–935.
Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G. Oxidative stress in Alzheimer’s disease. Biochim Biophys Acta 2000;1502:139–144.
Youdim MB. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and M30. Curr Alzheimer Res 2006;3:541–550.
Youdim MB, Buccafusco JJ. CNS Targets for multi-functional drugs in the treatment of Alzheimer’s and Parkinson’s diseases. J Neural Transm 2005.
Youdim MB, Buccafusco JJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 2005;26:27–35.
Bullock R. Future directions in the treatment of Alzheimer’s disease. Expert Opin Investig Drugs 2004;13: 303–314.
Tsolaki M, Kokarida K, Iakovidou V, Stilopoulos E, Meimaris J, Kazis A. Extrapyramidal symptoms and signs in Alzheimer’s disease: prevalence and correlation with the first symptom. Am J Alzheimers Dis Other Demen 2001;16:268–278.
Selkoe DJ, Schenk D. Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003;43:545–584.
Schliebs R. Basal forebrain cholinergic dysfunction in Alzheimer’s disease-interrelationship with beta-amyloid, inflammation and neurotrophin signaling. Neurochem Res 2005;30:895–908.
Palmer AM, Stratmann GC, Procter AW, Bowen DM. Possible neurotransmitter basis of behavioral changes in Alzheimer’s disease. Ann Neurol 1988;23:616–620.
Newman SC. The prevalence of depression in Alzheimer’s disease and vascular dementia in a population sample. J Affect Disord 1999;52:169–176.
Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137–147.
Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, De-Kosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2002;72: 310–314.
Giacobini E. Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer’ disease. J Neural Transm 2002:181–187.
Racchi M, Mazzucchelli M, Porrello E, Lanni C, Govoni S. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol Res 2004;50:441–451.
Francis PT, Nordberg A, Arnold SE. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer’s disease? Trends Pharmacol Sci 2005;26:104–111.
Bullock R. Cholinesterase inhibitors and vascular dementia: another suing to their bow? CNS Drugs 2004;18:79–92.
Robert P. Understanding and managing behavioural symptoms in Alzheimer’s disease and related dementias: focus on rivastigmine. Curr Med Res Opin 2002;18:156–171.
Clark CM, Karlawish JH. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med 2003;138:400–410.
Klafki HW, Staufenbiel M, Komhuber J, Wiltfang J. Therapeutic approaches to Alzheimer’s disease. Brain 2006;129:2840–2855.
Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim MBH. A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:555–561.
Weinstock M, Bejar C, Wang RH, et al. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer’s disease. J Neural Transm 2000;60:S157-S170.
Weinstock M, Kirschbaum-Slager N, Lazarovici P, Bejar C, Youdim MBH, Shoham S. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann N Y Acad Sci 2001;939:148–161.
Sterling J, Herzig Y, Goren T, et al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer’s disease. J Med Chem 2002;45:5260–5279.
Maruyama W, Weinstock M, Youdim MB, Nagai M, Naoi M. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett 2003;341:233–236.
Yogev-Falach M, Bar-Am O, Amit T, Weinreb O, Youdim MB. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. Faseb J 2006;20:2177–2179.
Buccafusco JJ, Terry AV Jr, Goren T, Blaugrun E. Potential cognitive actions of (n-propargly-(3r)-aminoindan-5-yl)-ethyl, methyl carbamate (tv3326), a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task. Neuroscience 2003;119:669–678.
Weinstock M, Poltyrev T, Bejar C, Youdim MB. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology 2002;160:318–324.
Youdim MBH, Wadia A, Tatton W, Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann N Y Acad Sci 2001;939:450–458.
Poltyrev T, Gorodetsky E, Bejar C, Schorer-Apelbaum D, Weinstock M. Effect of chronic treatment with ladostigil (TV-3326) on anxiogenic and depressive-like behaviour and on activity of the hypothalamic-pituitary-adrenal axis in male and female prenatally stressed rats. Psychopharmacology 2005;181:118–125.
Sagi Y, Drigues N, Youdim MB. The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats. Br J Pharmacol 2005;146: 553–560.
Shoham S, Bejar C, Kovalev E, Schorer-Apelbaum D, Weinstock M. Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats. Neuropharmacology 2007;52:836–843.
Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci 1998;158:47–52.
Pinero DJ, Hu J, Connor JR. Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer’s diseased brains. Cell Mol Biol 2000;46:761–776.
Smith MA, Hirai K, Hsiao K, et al. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 1998;70:2212–2215.
Moreira PI, Honda K, Liu Q, et al. Oxidative stress: the old enemy in Alzheimer’s disease pathophysiology. Curr Alzheimer Res 2005;2:403–408.
Honda K, Smith MA, Zhu X, et al. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem 2005;280:20978–20986.
Connor JR, Menzies SL, St Martin SM, Mufson EJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer’s diseased brains. J Neurosci Res 1992;31:75–83.
Yamada T, Tsujioka Y, Taguchi J, et al. Melanotransferrin is produced by senile plaque-associated reactive microglia in Alzheimer’s disease. Brain Res 1999;845:1–5.
Bush AI. The metallobiology of Alzheimer’s disease. Trends Neurosci 2003;26:207–214.
House E, Collingwood J, Khan A, Korchazkina O, Berthon G, Exley C. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer’s disease. J Alzheimers Dis 2004;6:291–301.
Yamamoto A, Shin RW, Hasegawa K, et al. Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer’s disease. J Neurochem 2002;82:1137–1147.
Rogers JT, Randall JD, Cahill CM, et al. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer’s amyloid precursor protein transcript. JBC 2002;277:45518–45528.
Zheng H, Weiner LM, Bar-Am O, et al. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. Bioorg Med Chem 2005;13:773–783.
Ben-Shachar D, Kahana N, Kampel V, Warshawsky A, Youdim MBH. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 2004;46:254–263.
Gal S, Zheng H, Fridkin M, Youdim MB. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain mono-amine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 2005;95:79–88.
Zhu W, Xie W, Pan T, et al. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. Faseb J 2007;21:3835–3844.
Zheng HGS, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, Youdim MBH. Novel multifunctional neuroprotective iron chelator-monoamine oxidase drugs for neurodegenerative diseases: i. in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 2005;95:68–78.
Pakaski M, Kasa P. Role of acetylcholinesterase inhibitors in the metabolism of amyloid precursor protein. Curr Drug Targets CNS Neurol Disord 2003;2:163–171.
Yogev-Falach M, Amit T, Bar-Am O, Sagi Y, Weinstock M, Youdim MBH. Implications of APP processing, PKC and marcks-phospharylation by rasagiline. Neural Plast 2002;9:124.
Shaw KT, Utsuki T, Rogers J, et al. Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci U S A 2001;98:7605–7610.
Greig NH, Utsuki T, Yu Q, et al. A new therapeutic target in Alzheimer’s disease treatment: attention to butyrylcholinesterase. Cuir Med Res Opin 2001;17:159–165.
Chong YH, Suh YH. Amyloidogenic processing of Alzheimer’s amyloid precursor protein in vitro and its modulation by metal ions and tacrine. Life Sci 1996;59:545–557.
Lahiri DK, Farlow MR, Nurnberger JI Jr, Greig NH. Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures. Ann N Y Acad Sci 1997;826:416–421.
Racchi M, Sironi M, Caprera A, König G, Govoni S. Short and long-term effect of acetylcholinesterase inhibition on the expression and metabolism of the amyloid precursor protein. Mol Psychiatry 2001;6:520–528.
Mazzucchelli M, Porrello E, Villetti G, Pietra C, Govoni S, Racchi M. Characterization of the effect of ganstigmine (CHF2819) on amyloid precursor protein metabolism in SH-SY5Y neuroblastoma cells. J Neural Transm 2003;110:935–947.
Zimmermann M, Gardoni F, Marcello E, et al. Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J Neurochem 2004;90:1489–1499.
Lahiri DK, Farlow MR. Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines. J Mol Neurosci 1996;7:41–49.
Pakaski M, Rakonczay Z, Kasa P. Reversible and irreversible acetylcholinesterase inhibitors cause changes in neuronal amyloid precursor protein processing and protein kinase C level in vitro. Neurochem Int 2001;38:219–226.
Zhang HY, Yan H, Tang XC. Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-alpha in intracerebroventricular beta-amyloid-(1–40) infused rats and human embryonic kidney 293 Swedish mutant cells. Neurosci Lett 2004;360:21–24.
Mamelak M. Alzheimer’s disease, oxidative stress and gamma-hydroxybutyrate. Neurobiol Aging 2007;28: 1340–1360.
Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001;60:759–767.
Rhee SG, Kim KH, Chae HZ, et al. Antioxidant defense mechanisms: a new thiol-specific antioxidant enzyme. Ann N Y Acad Sci 1994;738:86–92.
Stone JR, Yang S. Hydrogen peroxide: a signaling messenger. Antioxid Redox Signal 2006;8:243–270.
Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992;59:1609–1623.
Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 2001;18:685–716.
Zhang L, Yu H, Sun Y, et al. Protective effects of salidroside on hydrogen peroxide-induced apoptosis in SH-SY5Y human neuroblastoma cells. Eur J Pharmacol 2007;564:18–25.
Schallreuter KU, Elwary S. Hydrogen peroxide regulates the cholinergic signal in a concentration dependent manner. Life Sci 2007;80:2221–2226.
Xiao XQ, Lee NT, Carlier PR, Pang Y, Han YF. Bis(7)-tacrine, a promising anti-Alzheimer’s agent, reduces hydrogen peroxide-induced injury in rat pheochromocytoma cells: comparison with tacrine. Neurosci Lett 2000;290:197–200.
Xiao XQ, Yang JW, Tang XC. Huperzine A protects rat pheochromocytoma cells against hydrogen peroxide-induced injury. Neurosci Lett 1999;275:73–76.
Bar-Am O, Weinreb O, Amit T, Youdim MB. The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats. J Mol Neurosci 2008. DOI 10.1007/s12031-008-9139-6.
Weinreb O, Bar-Am O, Amit T, Drigues N, Sagi Y, Youdim MB. The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity. Chem Biol Interact 2008;175:318–326.
Ba F, Pang PK, Benishin CG. The establishment of a reliable cytotoxic system with SK-N-SH neuroblastoma cell culture. J Neurosci Methods 2003;123:11–22.
Stringer JL, Gaikwad A, Gonzales BN, Long DJ Jr., Marks LM, Jaiswal AK. Presence and induction of the enzyme NAD(P)H: quinone oxidoreductase 1 in the central nervous system. J Comp Neurol 2004;471: 289–297.
Zafar KS, Inayat-Hussain SH, Siegel D, Bao A, Shieh B, Ross D. Overexpression of NQO1 protects human SK-N-MC neuroblastoma cells against dopamine-induced cell death. Toxicol Lett 2006;166: 261–267.
SantaCruz KS, Yazlovitskaya E, Collins J, Johnson J, DeCarli C. Regional NAD(P)H:quinone oxidoreductase activity in Alzheimer’s disease. Neurobiol Aging 2004;25:63–69.
Maruyama W, Naoi M. Neuroprotection by (−)-deprenyl and related compounds Mech Ageing Dev 1999;111:189–200.
Weinstock M, Kirschbaum-Slager N, Lazarovici P, Bejar C, Shoami E, MBH Y. Cell culture and in vivo neuroprotective effects of novel cholinesterase-MAO inhibitors, derived from rasagiline as potential anti-Alzheimer drugs. Ann N Y Acad Sci 2000;939:148–161.
Carrillo MC, Minami C, Kitani K, et al. Enhancing effect of rasagiline on Superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 2000;67:577–585.
Dragoni S, Porcari V, Travagli M, Castagnolo D, Valoti M. Antioxidant properties of propargylamine derivatives: assessment of their ability to scavenge peroxynitrite. J Pharm Pharmacol 2006;58:561–565.
Yang L, He HY, Zhang XJ. Increased expression of intranuclear AChE involved in apoptosis of SK-N-SH cells. Neurosci Res 2002;42:261–268.
Toiber D, Soreq H. Cellular stress reactions as putative cholinergic links in Alzheimer’s disease. Neurochem Res 2005;30:909–919.
Calderon FH, von Bemhardi R, De Ferrari G, Luza S, Aldunate R, Inestrosa NC. Toxic effects of acetylcholinesterase on neuronal and glial-like cells in vitro. Mol Psychiatry 1998;3: 247–255.
Villarroya M, Garcia AG, Marco JL. New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer’s disease. Curr Pharm Des 2004;10:3177–3184.
Wang R, Tang XC. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer’s disease. Neurosignals 2005;14:71–82.
Sweatt JD. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 2001;76:1–10.
Luques L, Shoham S, Weinstock M. Chronic brain cytochrome oxidase inhibition selectively alters hippocampal cholinergic innervation and impairs memory: prevention by ladostigil. Exp Neurol 2007;206:209–219.
Weinreb O, Amit T, Bar-am O, Youdim MBH. Induction of the neurotrophic factors, GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: New insights and implication for therapy. Ann N Y Acad Sci 2007;1122:155–168.
Siegel GJ, Chauhan NB. Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain. Brain Res Brain Res Rev 2000;33:199–227.
Shen L, Figurov A, Lu B. Recent progress in studies of neurotrophic factors and their clinical implications. J Mol Med 1997;75:637–644.
Segal RA, Greenberg ME. Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci 1996;19:463–489.
Murakami H, Iwashita T, Asai N, et al. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation. Biochem Biophys Res Commun 1999;262:68–75.
Ting JT, Kelley BG, Sullivan JM. Synaptotagmin IV does not alter excitatory fast synaptic transmission or fusion pore kinetics in mammalian CNS neurons. J Neurosci 2006;26:372–380.
Youdim MB, Fridkin M, Zheng H. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson’s disease and other neurodegenerative diseases. J Neural Transm 2004;111: 1455–1471.
Borisenko GG, Kagan VE, Hsia CJ, Schor NF. Interaction between 6-hydroxydopamine and transferrin: “Let my iron go.” Biochemistry 2000;39:3392–3400.
van Acker SA, van den Berg DJ, Tromp MN, et al. Structural aspects of antioxidant activity of flavonoids. Free Radic Biol Med 1996;20:331–342.
Van der Schyf CJ, Gal S, Geldenhuys WJ, Youdim MB. Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opin Investig Drugs 2006;15:873–886.
Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M, Youdim MB. Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhbitor drug, M-30, for the treatment of Alzheimer’s disease. J Neurochem 2007;100:490–502.
Avramovich-Tirosh Y, Reznichenko L, Amit T, et al. Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable ironchelating-antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res 2007;4:403–411.
Ward MW, Kogel D, Prehn JH. Neuronal apoptosis: BH3-only proteins the real killers? J Bioenerg Biomembr 2004;36:295–298.
Copani A, Condorelli F, Caruso A, et al. Mitotic signaling by beta-amyloid causes neuronal death. Faseb J 1999;13:2225–2234.
Wu Q, Combs C, Cannady SB, Geldmacher DS, Herrup K. Beta-amyloid activated microglia induce cell cycling and cell death in cultured cortical neurons. Neurobiol Aging 2000;21:797–806.
Amit T, Avramovich-Tirosh Y, Youdim MB, Mandel S. Targeting multiple Alzheimer’s disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. Faseb J 2008;22:1296–1305.
Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005;4:71–78.
Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr Opin Struct Biol 2006;16:127–136.
Thal DR, Del Tredici K, Braak H. Neurodegeneration in normal brain aging and disease. Sci Aging Knowledge Environ; 2004:134.
Youdim MBH, Riederer P. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J Neural Transm 1993;91:181–195.
Weinstock M, Goren T, Youdim MBH. Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer’s disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Dev Res 2000;50:216–222.
Youdim MB, Amit T, Bar-Am O, Weinstock M, Yogev-Falach M. Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326. Ann N Y Acad Sci 2003;993: 378–386.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Weinreb, O., Mandel, S., Bar-Am, O. et al. Multifunctional neuroprotective derivatives of rasagiline as anti-alzheimer’s disease drugs. Neurotherapeutics 6, 163–174 (2009). https://doi.org/10.1016/j.nurt.2008.10.030
Issue Date:
DOI: https://doi.org/10.1016/j.nurt.2008.10.030